Sintx Q1 Revenue Beats Estimates, Secures FDA Clearance for Foot & Ankle System
SINT sits 16% above its 52-week low of $1.99.
Summary
Sintx Technologies reported first-quarter 2026 revenue of $380K, surpassing analyst estimates of $300K and marking a 3% year-over-year increase (46% from continuing operations). Despite a widened net loss of $(2.821M), the company announced significant operational progress, including FDA 510(k) clearance for its SiNAPTIC Foot & Ankle Osteotomy Wedge System and initial sales in Q1. These developments, coupled with cost-reduction initiatives expected to save $1M, are material for a micro-cap company that previously expressed substantial doubt about its ability to continue. Traders will be watching for sustained revenue growth from new products and the impact of cost savings on future financial performance.
At the time of this announcement, SINT was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $1.99 to $6.78. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.